August 17, 2002
Carbo/paclitaxel improves OS in women with epithelial ovarian cancer
(1) Carboplatin AUC 5
- q3wks x6 cycles
(2) Cyclophosphamide 500mg/m2
Doxorubicin 50mg/m2
Cisplatin 50mg/m2
- q3wks x6 cycles
Carboplatin AUC 5
Paclitaxel 175mg/m2 over 3hrs
- q3wk x6 cycles
Clinician certain that patient requires chemotherapy
Confirmed invasive epithelial ovarian cancer after surgery
Prior chemoRT
Median f/u: 51 mos
Carbo/paclitaxel (n=610) vs (1) and (2) (total n=1364):
Median PFS: 17.3 vs 16.1 mos (NS)
Median OS: 36.1 vs 35.4 mos (NS)
Alopecia highest in (2) and carbo/paclitaxel (~75%)
Sensory neuropathy highest in carbo/paclitaxel (~20%)
Single agent carboplatin and (2) are as effective as carbo/paclitaxel as first line treatment for women with epithelial ovarian cancer. Side effect profile favors single agent carbo.